Insmed Incorporated (NASDAQ:INSM) Insider Sells $114,423.84 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,744 shares of Insmed stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $65.61, for a total value of $114,423.84. Following the sale, the insider now owns 90,013 shares in the company, valued at $5,905,752.93. This trade represents a 1.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total value of $570,146.48.

Insmed Trading Up 1.3%

NASDAQ:INSM opened at $68.12 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The stock has a market capitalization of $12.41 billion, a price-to-earnings ratio of -12.19 and a beta of 0.84. The stock has a fifty day moving average price of $71.57 and a two-hundred day moving average price of $73.10.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. During the same period in the previous year, the business earned ($1.06) earnings per share. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently modified their holdings of INSM. Cullen Frost Bankers Inc. grew its position in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares during the period. Elequin Capital LP acquired a new stake in Insmed in the 4th quarter worth about $28,000. Steward Partners Investment Advisory LLC grew its holdings in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the period. NBC Securities Inc. acquired a new position in shares of Insmed during the 1st quarter valued at about $49,000. Finally, V Square Quantitative Management LLC lifted its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 248 shares during the period.

Analysts Set New Price Targets

INSM has been the subject of a number of research reports. Jefferies Financial Group began coverage on Insmed in a research note on Tuesday. They issued a “buy” rating and a $105.00 price objective for the company. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Finally, Truist Financial increased their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.